~~<i id='6C3B39FA3D'><strike id='6C3B39FA3D'><tt id='6C3B39FA3D'><pre id='6C3B39FA3D'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：comprehensive 2025-09-28 11:43:36 Page View：31962

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pushing for an NIH office for post
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

comprehensive

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Why doctors need education on FDA device approval process

AdobeInherfinalpresentationforhealthpolicyclassattheUniversityofChicago,first-yearmedicalstudentRobi